<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303546</url>
  </required_header>
  <id_info>
    <org_study_id>VOPITB STUDY</org_study_id>
    <nct_id>NCT04303546</nct_id>
  </id_info>
  <brief_title>VOPITB a New Devices to Determine Peripheral Arterial Stiffness: Validation Study</brief_title>
  <official_title>VOPITB a New Devices to Determine Peripheral Arterial Stiffness: Protocol for Validation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Extremadura</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Extremadura</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our group has developed a device called &quot;Velocidad Onda de Pulso Indice Tobillo Brazo&#xD;
      (VOPITB)&quot; . In this device the oscillometric method is used for easily and accurately measure&#xD;
      the pulse wave velocity PWV in the arms and legs separately, allowing new arterial stiffness&#xD;
      indices to be studied (sum, difference, ratio, baPWV and CAVI). The aim of our study will be&#xD;
      to validate the PWV measures by VOPITB with other references devices that measures arterial&#xD;
      stiffness. Moreover we will perform a clinical study to assess the clinical utility of&#xD;
      VOPITB.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 8, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>8 Months</target_duration>
  <primary_outcome>
    <measure>cardio-ankle vascular index (CAVI) validation</measure>
    <time_frame>8 months</time_frame>
    <description>We will determine CAVI with VOPITB, as well as its validation against the reference device (VaSera VS-1500) and assess its clinical utility.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Atherosclerosis of Artery</condition>
  <arm_group>
    <arm_group_label>&lt; 30 years</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>30-60 years</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>&gt; 60 years</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>arterial stiffness measurements</intervention_name>
    <description>We will measure arterial stiffness by VOPITB and with others devices to validate VOPITB</description>
    <arm_group_label>30-60 years</arm_group_label>
    <arm_group_label>&lt; 30 years</arm_group_label>
    <arm_group_label>&gt; 60 years</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The sample size has been calculated in order to provide that a difference between the CAVI&#xD;
        values obtained from measurement of both devices, VOPITB and VaSera, shall be up to of 0.8&#xD;
        points in comparison with the CAVI reference values for Spanish adults population [21]. the&#xD;
        base parameters used to calculate the sample size were as follows: standard deviation (sd)&#xD;
        of CAVI measured by VaSera VS-1500 and VOPITB (1.44), mean difference between CAVI&#xD;
        measurements (0.8), confidence level (95%), and power (80%). Thus, the estimated sample&#xD;
        size was found as 102 patients. In addition, for compensating possible incomplete data sets&#xD;
        from patients who could withdraw or fail to complete the study, 20% were added. Finally, a&#xD;
        total of 120 subjects (a minimum of 40% of subjects for each gender group) will be&#xD;
        evaluated according to the following criteria:&#xD;
&#xD;
          -  &lt; 30 years (40 subjects)&#xD;
&#xD;
          -  30 - 60 years (40 subjects)&#xD;
&#xD;
          -  &gt; 60 years (40 subjects)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects ≥ 18 years who agree to participate in the study and do not meet any of the&#xD;
             exclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of CVD (ischaemic heart disease, stroke or peripheral arterial disease)&#xD;
&#xD;
          -  Atrial fibrillation or other cardiac rhythm disorders&#xD;
&#xD;
          -  Pacemaker-dependent&#xD;
&#xD;
          -  Impalpable arterial pulse at site of measurement&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Terminal condition&#xD;
&#xD;
          -  Age under 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 8, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Extremadura</investigator_affiliation>
    <investigator_full_name>Sergio Rico Martín</investigator_full_name>
    <investigator_title>PhD. RN. Associate Professor</investigator_title>
  </responsible_party>
  <keyword>arterial stiffnes</keyword>
  <keyword>pulse wave velocity</keyword>
  <keyword>VOPITB</keyword>
  <keyword>validation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

